Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Debt: 2019-2025

Historic Non-Current Debt for BridgeBio Pharma (BBIO) over the last 6 years, with Sep 2025 value amounting to $740.4 million.

  • BridgeBio Pharma's Non-Current Debt rose 69.73% to $740.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $740.4 million, marking a year-over-year increase of 69.73%. This contributed to the annual value of $738.9 million for FY2024, which is 65.50% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Non-Current Debt of $740.4 million as of Q3 2025, which was up 0.20% from $738.9 million recorded in Q4 2024.
  • Over the past 5 years, BridgeBio Pharma's Non-Current Debt peaked at $740.4 million during Q3 2025, and registered a low of $90.8 million during Q1 2021.
  • In the last 3 years, BridgeBio Pharma's Non-Current Debt had a median value of $440.5 million in 2023 and averaged $505.6 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Non-Current Debt declined by 1.79% in 2021, and later surged by 378.30% in 2022.
  • Over the past 5 years, BridgeBio Pharma's Non-Current Debt (Quarterly) stood at $430.8 million in 2021, then grew by 0.06% to $431.0 million in 2022, then increased by 3.59% to $446.4 million in 2023, then soared by 65.50% to $738.9 million in 2024, then soared by 69.73% to $740.4 million in 2025.
  • Its Non-Current Debt was $740.4 million in Q3 2025, compared to $738.9 million in Q4 2024 and $436.2 million in Q3 2024.